September 14th, 2026FDA Grants Priority Review to Zasocitinib for Plaque PsoriasisTakeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.Read more